Clinical Trials Logo

Recurrence clinical trials

View clinical trials related to Recurrence.

Filter by:

NCT ID: NCT03799744 Not yet recruiting - Clinical trials for Head and Neck Neoplasms

Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma

Start date: February 28, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. VCN-01 is a genetically modified oncolytic adenovirus characterized by the presence of four independent genetic modifications on the backbone of the wild-type HAd5 adenovirus genome, encoding human PH20, that confer tumor selectivity and anti-tumor activity. Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1. The proposed mechanism of action (MOA) for durvalumab is interference in the interaction of PD-L1 with PD-1 and CD80 (B7.1). Blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses, including those that may result in tumor elimination.

NCT ID: NCT03799224 Recruiting - Clinical trials for Stem Cell Transplant Complications

Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia

Start date: December 1, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains one of the currently available curative therapies for acute leukemia (AL). Leukemia relapse is one of the mainly causes of transplant failure. We reported previously that patients with relapse or refratory AL were at very high risk of relapse post allo-HSCT, with cumulative relapse rate of 50-80%. Decitabine has been demonstrated efficacy in the treatment of patients with recurrent or refractory leukemia and myelodysplastiv syndrome. It was reported that the combination of decitabine, with busufan and cyclophosphamide as a preparative regimen for allo-HSCT using HLA-matching donors was safe and effective. In this prospective, single-arm clinical trial, we aimed to examine the efficacy of combining decitabine with modified busulfan and cyclophosphamide (mBU/CY) as a preparative regimen for allo-HSCT in recurrent and refracoty AL patients.

NCT ID: NCT03793517 Recruiting - Clinical trials for Leukemia, Myeloid, Acute

Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT

Start date: September 1, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains one of the currently available curative therapies for acute leukemia (AL). Leukemia relapse is one of the mainly causes of transplant failure. We reported previously that patients with high-risk molecular biomarkers who still have detectable minimal residual disease(MRD) pre-HSCT were at very high risk of relapse, with cumulative relapse rate of 50-80%. Decitabine has been demonstrated efficacy in the treatment of patients with recurrent or refractory leukemia and myelodysplastiv syndrome. It was reported that the combination of decitabine, with busufan and cyclophosphamide as a preparative regimen for allo-HSCT using HLA-matching donors was safe and effective. In this prospective, single-arm clinical trial, we aimed to examine the efficacy of combining decitabine with modified busulfan and cyclophosphamide (mBU/CY) as a preparative regimen for allo-HSCT in patients with very high-risk AL and detectable MRD pre-HSCT.

NCT ID: NCT03788434 Recruiting - Clinical trials for Clostridium Difficile Infection

Randomized Phase 2 Study of VE303 for Prevention of Recurrent Clostridium Difficile Infection

CONSORTIUM
Start date: December 2018
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of VE303 for participants with recurrent Clostridium difficile infection (rCDI).

NCT ID: NCT03787251 Not yet recruiting - Clinical trials for Esophageal Neoplasms

A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib

Start date: January 1, 2019
Phase: Phase 2
Study type: Interventional

A study of second-line treatment of postoperative recurrence and metastasis of esophageal squamous cell carcinoma after chemotherapy with apatinib mesylate

NCT ID: NCT03778710 Recruiting - Gastric Cancer Clinical Trials

Effect of Lymph Node Ratio in Gastric Cancer to Determine Recurrence Rate After Curative Resection

Start date: December 18, 2018
Phase:
Study type: Observational

D2 gastrectomy is standard treatment of early gastric cancer in Japan but in other countries there is still some discord, especially in Europe and North America. Although the quantity of metastasis cancer in lymph node defines survival regardless of which country the patient is treated, the total number of lymph nodes harvested is an important factor to predict accurate staging and/or D2 gastrectomy. Both of the number total lymph nodes and the metastasis lymph node status in gastric cancer are important factors to decide each prognosis. This study evaluated the correlation between total lymph nodes retrieved and metastasis node by lymph node ratio (LNR) status to determine the recurrence rate after curative resection of gastric

NCT ID: NCT03772197 Completed - Breast Cancer Clinical Trials

Parallel Comparison of 18 Gene Classifiers and Oncotype DX (Nanostring)

Start date: June 1, 2018
Phase:
Study type: Observational

A recurrence index for distant recurrence (RI-DR), an 18-gene-based clinical-genomic model, has been developed for early-stage breast cancer (EBC). In this study, Investigators compared the prognostic performance of the RI-DR with the Oncotype DX (ODx) recurrence score (RS) for any recurrence risk type.

NCT ID: NCT03769922 Not yet recruiting - Clinical trials for Postoperative Surgical Recurrence

Postoperative Progression of the Disease Following Extensive Versus Limited Mesenteric Excision for Crohn's Disease

Start date: January 2019
Phase: N/A
Study type: Interventional

The study evaluates whether there is a reduction in the rate of postoperative progression of the disease following extensive mesenteric excision (EME), when compared to that of limited mesenteric excision (LME), in patients undergoing ileocolic resection for Crohn's disease. Half of participants will receive EME, while the other half will receive LME.

NCT ID: NCT03768349 Enrolling by invitation - Prostate Cancer Clinical Trials

Gallium-68 PSMA-11 and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer

Start date: January 3, 2019
Phase: Phase 2
Study type: Interventional

Imaging and staging of prostate cancer is critical for surgical and treatment planning. In this protocol we will image patients with suspected metastatic prostate cancer using 11C-Choline PET and Gallium-68 labeled HBED-CC PSMA (more commonly called 68Ga-PSMA-11) in order to demonstrate their utility in detecting prostate cancer.

NCT ID: NCT03767452 Recruiting - Peyronie's Disease Clinical Trials

Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response

Start date: October 4, 2018
Phase: Phase 4
Study type: Interventional

Subjects who have had an incomplete response to previous Xiaflex® will receive up to 4 additional cycles of treatment.